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EVOLUTIVE BEHAVIOR TOWARDS CARDIOMYOPATHY OF TREATED (NIFURTIMOX OR
BENZNIDAZOLE) AND UNTREATED CHRONIC CHAGASIC PATIENTS
Diana FABBRO de SUASNÁBAR, Enrique ARIAS, Mirtha STREIGER, María PIACENZA, Mónica INGARAMO, Mónica DEL BARCO & Norberto AMICONE
SUMMARY
The aim of this work was to compare the evolution of chronic chagasic untreated patients (UTPs) with that of benznidazole or
nifurtimox-treated patients (TPs).
A longitudinal study from a low endemic area (Santa Fe city, Argentina) was performed during an average period of 14 years.
Serological and parasitological analyses with clinical exams, ECG and X-chest ray were carried out. At the onset, 19/198 infected
patients showed chagasic cardiomyopathy (CrChM) while 179 were asymptomatic. In this latter group the frequency of CrChM
during the follow-up was lower in TPs compared with UTPs (3.2% vs 7%). Within the CrChM group, 2/5 TPs showed aggravated
myopathy whereas this happened in 9/14 UTPs. Comparing the clinical evolution of all patients, 5.9% of TPs and 13% of UTPs had
unfavourable evolution, but the difference is not statistically relevant.
Serological titers were assessed by IIF. Titers equal to or lower than 1/64 were obtained in 86% of the TPs, but only in 38% of
UTPs. The differences were statistically significant (geometric mean: 49.36 vs. 98.2).
Antiparasitic assessment of the drugs (xenodiagnosis) proved to be effective. The low sensitivity in chronic chagasic patients
must be born in mind.
Despite treated patients showed a better clinical evolution and lower antibody levels than untreated ones, it is necessary to carry
on doing research in order to improve therapeutic guidelines, according to the risk/benefit equation and based on scientific and ethical
principles.
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INTRODUCTION
The specific antiparasitic treatment of Chagas’ disease has been the
subject of much controversy.
Many attempts have been done to find an appropriate drug which showed
both a highly trypanocidal action and low or null toxicity for the host.
Many drugs have been experimentally assayed, nitrofurane and
nitroimidazole derivatives as nifurtimox and beznidazole having shown
the highest efficacy against circulating trypomastigotes1,2,11, even in their
tissue forms3,12,15.
Studies conducted to find out how both drugs behave have revealed
that they are effective during the acute phase8,10,16 and in the case of
children under 331,37 that have already overcome this stage.
If the treatment is good enough to make the antigenic stimulus
disappear, we could expect a gradual decrease in anti-T. cruzi antibodies
to occur until negative values are confirmed. Although this process is
known to occur during the acute phase, it is uncertain whether the same
happens during the chronic phase4,8,20.
It is difficult to evaluate how effective are the therapy results in the
case of chronic patients, since Chagas’ disease progresses very slowly
and patient follow up has to be carried out during long periods. Both
conventional parasitological methods (xenodiagnosis and haemoculture),
which are known to be scarcely sensitive during this period, and the
post-treatment persistence of anti-T. cruzi antibodies have entangled the
evaluation.
As both cellular and humoral immunity have been related to the
disease24,33, the ethiological treatment during the chronic stage has become
more controversial.
Some researchers claim that these trypanocidal drugs (nifurtimox
and benznidazole) are not useful in preventing Chagas’ disease from
developing into a chronic infection38.
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The aim of our work was to make a follow-up of chronically-infected
patients from a low-endemic area, so as to study the natural evolution of
the disease in a group of non-treated patients and compare their evolutive
behaviour with that of patients undergoing a specific antiparasite
treatment.
MATERIAL AND METHODS
Design: nested cases and controls.
This research was carried out in Santa Fe city (Province of Santa
Fe), Argentina, from 1970 to 1998.
Patients suffering from chronic Chagas’ disease (n=492) were
selected by means of sampling dures carried out in different labor areas.
Those who came to our Center, either spontaneously or from other
services, for Chagas serology were also included.
The cohort was selected according to actual residence (Santa Fe city
and its outskirts) and age (older than 13, younger than 60). Absence of
specific antiparasitic treatment was also considered.
Data about migration, habitation, transfusion and maternal serology
antecedents were collected by anamnesis.
At the beginning, the population (grouped according to age) was
distributed in groups of similar size. During the follow-up period, many
patients left the study, in spite of having repeatedly made an appointment.
This undoubtedly distorted the groups, but the results are nevertheless
reported, in view of the long-term follow up.
All the patients underwent the following tests both at the beginning
and during the follow-up period:
a) Three serological Chagas-specific reactions: Direct agglutination
with 2-mercaptoethanol (DA-2ME), Indirect
Haemoagglutination (IHA) and Indirect Immunofluorescence
(IIF) using total human anti-immunoglobulin. Titers equal to or
higher than 1/32 for at least two out of the three reactions were
considered as positive.
b) Clinical examination, including electrocardiogram (ECG) and
chest X-ray (Chest X-r). ECG were classified according to
conventional norms accepted for population surveys32.
The digestive forms of the Chagas’ disease were not investigated.
Those electrocardiographic changes attributable to chronic
chagasic myocardiopathy (CrChM) were7,34: complete right
bundle branch block (RBBB); left anterior fascicular block
(LAFB); LAFB+RBBB; frequent ventricular extrasistole (VE);
frequent VE associated to conduction disturbances; 2nd degree
atrioventricular block (AVB); complete AVB; electrical
inactivation areas (no antecedents of ischemic cardiopathy).
The infected patients were clinically classified according to
KUSCHNIR27:
Group 0: asymptomatic patients (no signs of heart failure), normal
ECG and chest X-ray showing normal cardiac area (CTR<0.50).
Group I: asymptomatic patients (no signs of heart failure). Altered
ECG (disturbances suggesting CrChM) and chest X-ray showing
normal cardiac area.
Group II: Altered ECG. Chest X-ray: enlarged cardiac area.
Functional capacity preserved during sligth to moderate efforts.
Group III: Strongly symptomatic patients, from a clinical point
of view (signs of heart failure either at rest or during slight
efforts), altered ECG and chest X-ray showing important
cardiomegaly (grades III or IV) with redistribution of lung flow.
c) The specific antiparasitic treatment included:
Nifurtimox: 5 to 8 mg/kg/day for 60 days.
Benznidazole: 5 mg/kg/day for 30 days: half a dose was provided
during the first week8,35.
It was not given to pregnant women; neither was it supplied to
people with hepatic, renal or haematologic failures.
All patients were treated before 1982. At that moment, the
administration period suggested for benznidazole was 30 days.
d) Clinical analysis and parasitological xenodiagnosis (Xd) (serial,
pre- and post- treatment) were performed on patients receiving
trypanocidal drugs. A high percentage (60%) of patients
underwent this study.
Both treated and untreated chronic chagasic patients were
controlled annually or every two years.
Study cohort
As time passed, the number of patients involved decreased; besides
those who returned to highly endemic areas, even for a short period of
time, were excluded.
With the aim of having those patients back, home visits were made
so as to know why they had stopped attending their checkup sessions.
The most important reason is reported to have been the socioeconomic
condition of patients, which made it very difficult for them to move
around, even within the city itself. Other reasons were migrations and/
or unacceptance of the infection, for fear of losing their job.
In this work we present test results from 198 patients periodically
controlled during 8 to 23 years (average: 14 years).
In the study group (n=198), 68 patients received specific antiparasitc
treatment: 34 with nifurtimox (Nx) and 36 with benznidazole (Bz). Two
patients were treated with both drugs. They were included in tables and
figures corresponding to the patient group treated with the last drug
given (benznidazole).
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RESULTS
At the beginning 86% of the study the infected people was 42 year-
old or less, while the most group was between 23 and 42 year-old
(Table 1).
Part of the population studied (88%) had been born, or had lived, in
highly endemic areas; in addition, 24% had received blood transfusions.
Among the rest of the nonmigrating patients, 8% had received transfusion;
it was definitely proved that 2% had been born from seropositive mothers,
while another 2% had no migration or transfusion antecedents, and
maternal serology was unknown.
The clinical classification of the patients was made only for chronic
chagasic myocardiopathy because the digestive forms of Chagas’ disease
were not studied.
Nineteen out of 198 (9.6%) chronic patients showed electro-
cardiographical and/or chest X-ray alterations which suggested chagasic
ethiology at the beginning of the study, while 179 were going through
the latent or undetermined period of the infection, with normal chest X-
ray and normal ECG (Figure 1).
In the latter group (n=179), only 63 patients received specific
antiparasitic treatment whereas 116 remained untreated.
2/63 infected individuals treated with benznidazole evolved towards
a more severe clinical group: 3.2% (32 and 34 year-old at the beginning
of the study, cases 1 and 2, Table 2). For patient 1, frequent VE were
observed 3 years after the treatment had finished (GI); LAFB and grade
I cardiomegaly are also detected 8 years later (GII). These disturbances
are still present after another period of 7 years. For patient 2, changes
began to be noticed 5 years after the treatment had ended (LAFB) (GI),
and 2 years later he presented grade I cardiomegaly (GII). From them
on, he has remained in this group (6 years).
Among the asymptomatic infected individuals who had not been
treated with specific antiparasitic drugs 8/116 (7%) had altered ECG
(Figure 1, Table 2).
Patient No. 5 (33 year-old) presented PR 0.26+IRBBB+VE after 12
years (GI), and 6 years later he evolved with first grade
AVB+RBBB+LAFB and grade I cardiomegaly (GII).
Case No. 8 (38 year-old) evolved after 9 years, showing
RBBB+VE+sinus bradycardia (SB) with normal cardiac area (GI). Two
years latter he presented grade I cardiomegaly (GII). He has remained in
this group until the last control (6 years).
The other 6 patients whose ECG changes shifted from group 0 to
group I. Patient No. 4 (31 year-old) evolved to RBBB. Four patients
presented single LAFB or LAFB associated to IRBBB or RBBB. At the
beginning, they were 25, 37, 40 and 41 years old respectively, and changes
were observed during a follow-up period of 9 to 14 years. Patient No. 7
showed frequent VE, V3 to V6 negative (-) T wave, after having been
monitored for 13 years.
Table 1
Age and sex distribuition at the beginning of the study and follow-up period
Treated Untreated
Age groups M F T Years of follow-up M F T Years of follow-up Total
Mean±SD Mean±SD
13 to 22 7 8 15 14.7 ± 4.49 13 15 28 12 ± 3.18 43
Nx:6
Bz:9
23 to 32 7 18 25 15.7 ± 4.35 18 22 40 13.5 ± 3.58 65
86% Nx:12
Bz:13
33 to 42 16 8 24 15 ± 3.67 13 24 37 14.2 ± 3.68 61
Nx:12
Bz:12
43 to 52 2 2 4 15.5 ± 2.38  6 14 20 14.8 ± 3.94 24
Nx:2
Bz:2
≥53  3   2   5 12.8 ± 3.85  5
Total 32 36 68 53 77   130   198
Nx:32
Bz:36
M: male F: female T: total Nx: nifurtimox Bz: benznidazole
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Fig. 1 - Clinical evolution of symptomatic and asymptomatic chronic chagasic patients according to whether they received or not trypanocidal drugs.
60
FABBRO de SUASNÁBAR, D.; ARIAS, E.; STREIGER, M.; PIACENZA, M.; INGARAMO, M.; DEL BARCO, M. & AMICONE, N. - Evolutive behavior towards cardiomyopathy of treated
(nifurtimox or benznidazole) and untreated chronic chagasic patients. Rev. Inst. Med. trop. S. Paulo, 42(2): 99-109, 2000.
103
In the untreated patients (n=8), the mean and median time of clinical
evolution (G0→GI) during the follow-up period was of 11 years.
In the group of patients with signs or symptoms of CrChM (n=19),
only 5 patients received specific antiparasitic treatment (Nx=3; Bz=2)
(Table 3); 2 of them (38 and 40 year-old) evolved towards a more severe
clinical group or died because of chagasic miocardiopathy (cases No. 3
and 4). The latter presented RBBB at the beginning (GI), while VE and
grade I cardiomegaly were detected 8 years later. He died after a follow-
up period of 13 years, due to heart arrest (sudden death because of
arrhythmia?).
Patient No. 3, showed RBBB+LAFB and normal chest X-ray (GI)
in the first control. After 12 years he developed first degree AVB and
grade I cardiomegaly (GII).
During the first examination, patient No. 5 showed complete AVB
with normal cardiac area, but a low functional capacity due to cardiac
frequency (effort-caused dyspnea). Twelve years later, without a
pacemaker having been implanted yet, the same symptoms were
observed. According to ECG pattern and chest X-ray, the patient belong
to Group I, although the clinical symptoms allowed us to classify the
case within Group II.
Nine out of fourteen untreated patients with electrocardiographic
and/or radiological alterations showed an unfavourable evolution (Table
3) and three of them died:
– a 38 year-old patient (No. 13), initially showing low-voltage QRS
complexes with frequent VE, normal cardiac area, and no signs of
heart failure. After 4 years, the patient developed a IRBBB with
low-voltage complexes and grade I cardiomegaly. After 8 years the
same symptoms were observed except for grade II cardiomegaly.
Three years afterwards, with grade III-IV cardiomegaly clinical and
radiological signs of heart failure, a pacemaker was implanted to
solve the bradyarrhythmia. After two years the patient died of heart
failure (monitored along 17 years).
Table 2
Clinical evolution of chronic chagasic patients in the latent phase at beginning. Developed lesions during the study (10/179)
No. AGE SEX T UT ICG FCG FP
 1  32  F  Bz  G0 GII 18
LAFB+frequent VE
Cardiomegaly grade I
 2  34  M  Bz  G0 GII 13
LAFB+SB
Cardiomegaly grade I
 3  25  F  X  G0 GI 11
IRBBB+LAFB
 4  31  F  X  G0 GI 13
RBBB
 5  33  F  X  G0 GII 18
1° AVB+RBBB+LAFB
Cardiomegaly grade I
 6  37  F  X  G0 GI 14
RBBB+LAFB
 7  37  M  X  G0 GI 13
Frequent VE, V3 to V6 (-)T
 8  38  M  X  G0 GII 17
RBBB+ VE+SB
Cardiomegaly grade I
 9  40  M  X  G0 GI 16
LAFB
 10  41  M  X  G0 GI 10
LAFB
T: treated; UT: untreated; ICG: initial clinical group; FCG: final clinical group; FP: follow-up period (years); G0-I-II: clinical group 0-I and II
(according to Kuschnir’s classification); 1°AVB: first-degree atrioventricular block; LAFB: left anterior fascicular block; VE: ventricular extrasistole;
SB: sinus bradycardia; IRBBB: incomplete right bundle branch; RBBB: complete right bundle branch block; Bz: benznidazole.
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Table 3
Clinical evolution og chronic patients showing signs or symptoms of chagasic miocardiopathy at beginning of the study
No.  AGE  SEX  T  UT  ICG  FCG  FP
 1  22  M  Bz GI GI 11
RBBB RBBB
Chest X-ray: normal Chest X-r: normal
 2  31  F  Bz GI GI 14
LAFB LAFB
Chest X-r: normal Chest X-r: normal
 3  38  M  Nx GI GII 14
RBBB+LAFB RBBB+LAFB+1°AVB
Chest X-r: normal Cardiomegaly grade I
 4  40  M  Nx GI GII 13 ?
RBBB RBBB+VE
Chest X-r: normal Cardiomegaly grade I
 5  46  M  Nx GI-II? GI-II? 13
Complete AVB Complete AVB
Chest X-r: normal Chest X-r: normal
6 22 M X GII GII 10
LAFB LAFB
Cardiomegaly grade I Cardiomegaly grade I
7 25 F X GI GII 18
LAFB LAFB+SB
Chest X-r: normal Cardiomegaly grade I
8 32 F X GII GII 13
RBBB+LAFB RBBB+LAFB
Cardiomegaly grade I Cardiomegaly grade I
9 33 M X GI GII 13
RBBB RBBB
Chest X-r: Normal Cardiomegaly grade I
10 34 F X GI GI 10
RBBB+LAFB RBBB+LAFB
Chest X-r: normal Chest X-r: normal
11 37 F X GI GI 10
LAFB LAFB
Chest X-r: normal Chest X-r: normal
12 37 M X GII GIII 17
LAFB IRBBB+LAFB
Cardiomegaly grade I Cardiomegaly grade II
Signs of heart failure
13 38 M X GI GIII 17  ?
VE low-voltage QRS IRBBB+VE+SB
complexes Cardiomegaly grade III
Chest X-1r: normal Signs of heart failure
Continue
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Continuation table 3
 14  39  F  X GII GII  11
RBBB+LAFB RBBB+LAFB
Cardiomegaly grade I Cardiomegaly grade I
 15  43  F  X GI GII  10
LAFB LAFB+APE
Chest X-r: normal Effort-caused dyspnea
Cardiomegaly grade I
 16  47  F  X GII GIII  8  ?
RBBB+LAFB RBBB+LAFB
Cardiomegaly grade I Cardiomegaly grade III
Signs of heart failure
 17  54  M  X GII GIII  18
LAFB LAFB+IRBBB+VE
Cardiomegaly grade I Cardiomegaly grade II
Sign of heart failure
 18  59  M  X GII GIII  13 ?
RBBB+LAFB RBBB+LAFB+SB
Cardiomegaly grade I With pacemaker
Cardiomegaly grade III
 19  59  M  X GI GIII  8
IRBBB+LAFB+1° AVB Complete AVB
Chest X-r: normal with pacemaker
cardiomegaly grade II
Sign of heart  failure
?: died; FP: follow-up period (years); ICG: initial clinical group; FCG: final clinical group; T: treated; UT: untreated; GI-II-III: clinical group I, II and
III (according to Kuschnir’s classification); RBBB: complete right bundle branch block; LAFB: left anterior fascicular block; 1°AVB: first-degree
atrioventricular block; VE: ventricular extrasistole; SB: sinus bradycardia; IRBBB: incomplete right bundle branch block; APE: atrial premature
ectopic; Bz: benznidazole; Nx: nifurtimox.
– a 47 year-old patient (No. 16) with RBBB+LAFB and grade I
cardiomegaly evolved to grade III, dying after several events of
ventricular fibrillation.
– a 59 year-old patient (No. 18) who at first showed RBBB+LAFB
and grade I cardiomegaly, and after 12 years developed symptomatic
sinus bradycardia. A pacemaker was implanted, but the patient died
6 months later from cardiac arrest (arrhythmia).
Patient No. 12, 37 year-old, initially showed LAFB and grade I
cardiomegaly. After a follow-up period of fifteen years, the patient
suffered a stroke and kept on with right hemiparesis two years later.
Serological tests were slightly positive during the first 3 years, and then
no anti-T. cruzi antibodies (Ab) could be detected, except for a few
positive results with direct agglutination tests. The results from 5 Xd
were negative.
In this group of untreated patients, the time of evolution from one
clinical group to another was highly variable. Those who changed from
GI to GII did this within 4 to 10 years (x=6.4). The greatest variations in
time were observed in patients whose cardiomyopathy was seen to
aggravate (GII→GIII) within 1 to 15 years.
It is necessary to comment on the actual evolution time in patients,
as it is not known how many years each chronic patient had been infected.
None of them knew they were infected when they first entered the study.
Nor did they know when they had acquired the infection.
Considering all the patients (n=198), with or without specific
antiparasitic treatment (Figure 2), the 5.9% of treated patients (n=68)
presented clinical group changes during the follow-up period, whereas
these modifications were observed in the 13% of untreated patients
(n=130).
Data analysis shows a favourable clinical evolution to exist in treated
patients although it is not statistically significant (Chi square test: not
significant; p>0.05) (Fisher exact test: not significant; p>0.05).
A group of 73 chronically infected patients (without signs or
symptoms of CrChM) who had undergone a longer monitoring period
(over 15 years) showed a favourable clinical evolution. If we include
two patients who developed first degree AVB in the group which showed
a non favourable evolution, this represents the 8.3% (6/73) and if we
exclude them, the 5.5% (4/73).
106
FABBRO de SUASNÁBAR, D.; ARIAS, E.; STREIGER, M.; PIACENZA, M.; INGARAMO, M.; DEL BARCO, M. & AMICONE, N. - Evolutive behavior towards cardiomyopathy of treated
(nifurtimox or benznidazole) and untreated chronic chagasic patients. Rev. Inst. Med. trop. S. Paulo, 42(2): 99-109, 2000.
198
130
17 113
68
Nx:32
Bz:36
4
Nx:2
Bz:2
64
Nx:30
Bz:34
untreated treated
C G changed No C G
changed
C G changed No C G
changed
13 % 87% 5,9% 94,1 %
CG changed: Clinical group changed
No ECG: No clinical group changed
Nx: nifurtimox
Bz: benznidazole
Fig. 2 - Evolutive electrocardiographical and radiological behavior of 198 chronic chagasic patients, with and without specific chemotherapy.
Half of the group received antiparasitic drugs (n=36), and showed a
lesser degree of CrChM when compared with non-treated patients. The
sample size does not allow us to arrive to a definite conclusion.
Serological titers
All the patient’s sera drawn during 1995 were simultaneously
analysed using indirect immunofluorescence against total Ig antibodies
(Ab). Among the 89 sera, 38 belonged to infected treated patients. The
majority (86%) showed antibody titers equal to or lower than 1/64. Two
patients who had been treated with antiparasitic drugs at the age of 14
and 15 (Nx=1, Bz=1), showed a progressive decrease in serological titers.
Non-reactive results for the three tests were obtained only 6 years after
the treatment had finished, and the parasitological tests (Xd) were
negative. These two patients, (now 29 and 30 years old respectively)
still show no signs or symptoms of CrChM.
Among the 51 sera from infected patients without treatment, 62%
showed serological titers equal to or higher than 1/128. Anti-T. cruzi Ab
were not detected by IIF in the serum from patient No. 8, described in
Table 3.
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Table 4 shows the median and geometric mean of the serological
titers by age groups in patients during a mean follow-up period of 15
years:
– In 4A between treated and untreated patients.
– In 4B between patients treated with nifurtimox or benznidazole.
Statistically significant differences (p<0.005) were observed between
IIF-assessed antibody titers of treated patients (geometric mean=49.36)
and those of non-treated ones (geometric mean=98.25). These differences
were not observed when patients treated with nifurtimox (geometric
mean=41.40) or benznidazole (geometric mean=44.16) were compared
(Fischer exact test: not significant; p>0.05).
Trypanocidal drug tolerance
In the group of patients treated with benznidazole, 5 out of 36 (13.8%)
did not tolerate the drug, erythema maculopapulatum and nausea being
the most frequent symptoms. Afterwards, three of them were treated
with nifurtimox.
In the group of patients treated with this last drug, 3/32 (9.4%) did
not tolerate it and 2 of them had (+) xenodiagnosis after having completed
the treatment. Nifurtimox intolerance manifested itself with nausea, vomit
and increased transaminase levels.
Parasitological studies
Serial Xd were carried out on samples from 129 chronic patients. T.
cruzi was shown in 54 patients (42%), 38 of which received treatment.
All post-treatment parasitological controls were negative (-), except for
2 patients to whom nifurtimox had been administered. They were
afterwards treated with benznidazole, the following studies showing that
their Xds had become negative.
As regard manifestation of clinical signs (electrocardiographical and/
or radiological alterations) related to the presence or absence of Xd-
demonstrable parasitemia, the following data were gathered:
– Only one of the 38 treated showing previous (+) Xd evolved towards
a more severe clinical stage, and presented 7 (-) post-treatment serial
Xd (case No. 1, Table 2). Two out of the 16 patients who did not
receive trypanocidal drugs developed electrocardiographical and/or
radiological alterations compatible with CrChM.
– Fifteen of the 75 patients who showed (-) Xd - some of them
repeatedly up to 8 times - received treatment with nifurtimox or
benznidazole, and 2 evolved towards a CrChM. In the non-treated
group (n=60), 13 patients fell ill or got worse.
DISCUSSION
Our results show that, when comparing data from non-treated patients
with those from patients who had received specific antiparasitological
treatment, the latter revealed a favourable clinical, electrocardiographical
and radiological evolution as well as a decrease in IIF-assessed serological
titers.
These findings are similar to those observed in benznidazole-treated
patients41 and differ from those found for chronically infected people
treated with nifurtimox28.
In our work differences were not observed as regards the clinical
and serological evolution between the patients treated with nifurtimox
or benznidazole.
Others authors have experimentally observed a decrease in both
anatomopathological lesions1,5,36 and anti-T. cruzi Ab level in chronically
infected mice treated with trypanocidal drugs (nifurtimox-benznidazole).
Besides, there exist certain T. cruzi strains that are known to be more
susceptible to a specific chemotherapy than others6.
There is evidence supporting the idea that autoimmune phenomena
are involved in the fisiopathogenia of CrChM: in heart histological studies
performed on biopsies and necropsies, the lesions found were
independent of the “in situ” T. cruzi presence, and the existence of
autoimmunity-associated antibodies was also demonstrated17,23. However,
it is possible that the presence of either the parasite or its specific antigenic
components9 could contribute to maintain or stimulate these
immunological phenomena.
Table 4
Serological titers (IIF) at the end of the study (years of follow-up: mean 15)
A) Treated and untreated patients
Age groups at Serological titers
the beginning Treated (n=38) Untreated (n=51)
No. m gm No. m gm
13 to 22 12 32 29.5 9 128 101.4
23 to 32 14 64 60.9 17 128 92.3
33 to 42 9 32 47 13 128 100
43 to 52 3 64 64 10 128 104
≥ 53 - - - 2 128 90.5
B) Patientes treated with Nifurtimox or Benznidazole
Age groups at Serological titers
the beginning Benznidazole (n=20) Nifurtimox (n=18)
No. m gm No. m gm
13 to 22 7 32 34.9 5 32 27.5
23 to 32 7 64 57.2 7 32 46.9
33 to 42 5 32 47.9 4 32 44.7
43 to 52 1 32 31.6 2 64 63.1
No.: number of serums
m: median
gm: geometric mean
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Others authors also observed a decrease in specific-antibody level
in chronic patients previously treated with trypanocidal drugs41. During
our follow-up, a positive serology persisted, except for 2 patients who
were treated at the ages of 14 and 15. They repeatedly showed titers
lower than the thereshold value (<1/32), for the three serological
reactions, more than 6 years after the treatment had finished. No signs
or symptoms of CrChM were revealed and their parasitological studies
(serial Xds) did not show T. cruzi.
The age at which chronic patients received treatment is considered
to be important since the lower the age of chronic chagasic treated
children, the higher the percentage of negative parasitological and
serological studies18,19, although the trypanocidal drugs used were shown
to be more effective during the acute stage and in children under 3.
Xd parasitological studies were negative in treated patients, but we
must take into account that the low sensitivity of this method during the
chronic period does not allow us to assert that complete deparasitation
has been achieved as a result of drug action.
The presence or absence of lytic antibodies has been used by some
authors21,29 as an important element to monitor treatment efficacy, but
the complement-mediated lysis test used for those antibodies presents
some difficulties from a practical point of view.
In diagnosing and evaluating trypanocidal drug action, it would be
greatly useful to deepen studies on the search for new techniques based
either on specific T. cruzi antigenic components22,25,26 or on the parasite
DNA recognition. Polymerase chain reaction (PCR) has been assayed
to evaluate benznidazole therapeutic action13 with encouraging results.
The evolution of treated and untreated asymptomatic chronic patients
after 15 years of follow-up is benign since only 5.5%-8.3% present
symptoms and/or signs of CrChM.
A correlation between T. cruzi zymodemes30 and the clinical picture
has been already shown to exist, but important factors other than the
parasite strain would be possibly involved, as the nutritional state of the
population under study, the possibility of reinfections, etc.
In spite of their toxicity14,39,40, nifurtimox and benznidazole are the
best clinically used drugs currently available. We believe it is important
to carry on research in order to clarify therapeutic guidelines about the
risk/benefit, based on scientific and ethical principles.
RESUMO
Evolução à miocardiopatia dos infectados chagásicos crônicos
tratados (nifurtimox ou benzonidazol) e não tratados
Para comparar a evolução dos infectados chagásicos crônicos não
tratados (UTPs) e tratados (TPs) com nifurtimox ou benznidazol, fez-se
um estudo longitudinal numa área de baixa endemicidade (cidade de
Santa Fe, Argentina), com média de seguimento de 14 anos.
Em cada controle foram feitas análises sorológicas e parasitológicas,
exames clínicos, eletrocardiográficos e radiológicos.
No inicio, 19/198 infectados apresentaram miocardiopatia chagásica
crônica (MChCr), enquanto 179 eram assintomáticos. A frequência de
MChCr no seguimento destes últimos foi 3,2% para os tratados e 7%
para os não tratados. Dos pacientes com MChCr no início, 2/5 dos tratados
e 9/14 dos não tratados agravaram sua miocardiopatia. Comparando a
evolução clínica dos infectados, 5,9% dos tratados e 13% dos não tratados
tiveram evolução desfavorável, mas esta diferença não é estatisticamente
significativa.
Na avaliação sorológica por IFI, 86% dos TPs e só 38% dos UTPs
apresentaram títulos menores ou iguais a 1/64. As diferenças são
estatisticamente significativas (média geométrica: 49,36 vs 98,2).
Os xenodiagnósticos seriados realizados, demonstraram efetividade
das drogas (considerar a baixa sensibilidade deste método na etapa
crônica).
Os pacientes tratados mostraram melhor evolução clínica e mais
baixos níveis de anticorpos do que os não tratados. É preciso continuar
as investigações para estabelecer pautas terapêuticas mais claras sobre a
relação risco-benefício, sustentadas nos princípios científicos e éticos.
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